Drug intelligence / Profile preview

TOTEKVIN

Development stage: Unknown
Lead developer: Institute Torlak
Modality: Antibody-Based Therapeutics
Administration: Intramuscular

Overview

TOTEKVIN is an equine-derived tetanus antitoxin serum developed and manufactured by the Torlak Institute of Virology, Vaccines and Sera. It contains purified and concentrated immunoglobulins obtained from horses immunized against tetanus toxin. The product provides immediate passive immunity by neutralizing the tetanus toxin produced by *Clostridium tetani*, preventing the toxin from binding to nervous system receptors. It is indicated for the post-exposure prophylaxis of tetanus in individuals with tetanus-prone injuries who have an incomplete or unknown vaccination history.

Brand names: TOTEKVIN
Other names: tetanus antitoxinequine tetanus antitoxintetanus antiserum

Beyond the preview

Go deeper on TOTEKVIN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOTEKVIN.

Explore the full profile